BMGL$0.7053

Basel Medical Group Ltd

Healthcare Facilities & ServicesVerified

Basel Medical Group Ltd has a market capitalization of SGD 13,150,025 and a market price of SGD 0.7 per share, with 18,785,750 basic and diluted shares outstanding. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and returns are not available for comparison with industry_config preferred metrics or cohort medians, as no relevant financial data is provided in the input. The company's segments and geographic exposure are not disclosed in the input data, making it impossible to assess revenue concentration or geographic diversification. The company's growth trajectory is not quantifiable due to the absence of outlook numeric deltas or revenue history in the input data. The company's risk assessment indicates a low dilution potential, with no significant risk factors identified in the input data. However, the lack of balance-sheet inputs and going-concern language prevents a full assessment of liquidity risk. Recent events, including filings and transcripts, are not disclosed in the input data, making it impossible to assess the company's recent developments or strategic direction.

30-day price · BMGL(missing data)

No daily-bar history available from current data sources. Alternate source pending.

Profile

CompanyBasel Medical Group Ltd

TickerBMGL.O

SectorHealthcare

BusinessHealthcare Services & Equipment

Industry groupHealthcare Services & Equipment

IndustryHealthcare Facilities & Services

AI analysis

Business. Basel Medical Group Ltd is a biotechnology company operating in the healthcare facilities and services industry, providing medical services and solutions.

Classification. The company is classified under the Healthcare economic sector, Healthcare Services & Equipment business sector, and Healthcare Facilities & Services industry with a confidence level of 0.92.

Key takeaways

Basel Medical Group Ltd operates in the healthcare facilities and services industry with a focus on biotechnology.
The company has a market capitalization of SGD 13,150,025 and a market price of SGD 0.7 per share.
Liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability, returns, and growth trajectory are not quantifiable due to the lack of relevant financial data.
The company's segments, geographic exposure, and recent events are not disclosed in the input data.
--
## RATIONALES
```json

Financial snapshot

PeriodHA-latest

CurrencySGD

Revenue—

Gross profit—

Operating income—

Net income—

R&D—

SG&A—

D&A—

SBC—

Operating cash flow—

CapEx—

Free cash flow—

Total assets—

Total liabilities—

Total equity—

Cash & equivalents—

Long-term debt—

Annual history (last 5)

PeriodRevenueOp IncomeNet IncomeFCF

FY-4————

FY-3$10.7M$4.3M$2.0M$1.9M

FY-2$9.7M$4.3M$1.8M$1.8M

FY-1$10.1M$4.4M$2.1M$2.1M

FY0$11.3M-$10.0M-$10.6M-$11.1M

PeriodGross %Op %Net %FCF %

FY-4————

FY-3————

FY-2————

FY-1————

FY0————

PeriodAssetsEquityCashDebt

FY-4————

FY-3$16.8M$3.7M——

FY-2$15.4M$5.5M——

FY-1$16.3M$7.6M——

FY0$18.7M$5.4M——

PeriodOCFCapExFCFSBC

FY-4————

FY-3$2.8M-$88.5k$1.9M—

FY-2$2.6M-$6.2k$1.8M—

FY-1$2.5M-$7.9k$2.1M—

FY0-$4.0M-$556.9k-$11.1M—

Quarterly history (last 4)

PeriodRevenueOp IncomeNet IncomeFCF

FQ-7————

FQ-6———$1.3M

FQ-5————

FQ-4———$760.5k

FQ-3————

FQ-2———-$314.9k

FQ-1————

FQ0———-$10.8M

PeriodGross %Op %Net %FCF %

FQ-7————

FQ-6————

FQ-5————

FQ-4————

FQ-3————

FQ-2————

FQ-1————

FQ0————

PeriodAssetsEquityCashDebt

FQ-7————

FQ-6$16.7M$6.8M——

FQ-5————

FQ-4$16.3M$7.6M——

FQ-3————

FQ-2$14.9M$7.3M——

FQ-1————

FQ0$18.7M$5.4M——

PeriodOCFCapExFCFSBC

FQ-7————

FQ-6$143.8k-$7.9k$1.3M—

FQ-5————

FQ-4$2.5M-$7.9k$760.5k—

FQ-3————

FQ-2-$3.8M-$18.4k-$314.9k—

FQ-1————

FQ0-$4.0M-$556.9k-$10.8M—

Valuation

Market price$0.70

Market cap$13.2M

Enterprise value—

P/E—

Reported non-GAAP P/E—

EV/Revenue—

EV/Op income—

EV/OCF—

P/B—

P/Tangible book—

Tangible book—

Net cash—

Current ratio—

Debt/Equity—

ROA—

ROE—

Cash conversion—

CapEx/Revenue—

SBC/Revenue—

Asset intensity—

Dilution ratio0.0%

Risk assessment

Dilution riskLow

Liquidity riskUnknown

Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).

Industry benchmarks

Activity: Biotechnology · cohort 117 companies

MetricBMGLActivity

Op margin—5.6% medp25 -4.2% · p75 12.6%

Net margin—2.8% medp25 -3.4% · p75 8.8%

Gross margin—36.5% medp25 23.7% · p75 65.2%

CapEx / revenue—-4.9% medp25 -11.5% · p75 -2.0%

Debt / equity—69.3% medp25 7.9% · p75 120.9%

Source data

Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.

Company fundamentalsperiod FQ-7 · history via verified-market-data

no public URL

2026-05-16 21:34 UTC#9b541e05

Market quoteclose SGD 0.58 · shares 0.02B diluted

no public URL

2026-05-16 21:34 UTC#93c472a9

Source: analysis-pipeline (hybrid)Generated: 2026-05-27 12:54 UTCJob: 2de002d6